oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2026-25-2-67-79oncotomsk-4201Research ArticleЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯLABORATORY AND EXPERIMENTAL STUDIESПараметры циркулирующих в крови опухолевых клеток в период проведения системной терапии при первичном раке молочной железыCirculating tumor cell parameters during systemic therapy in primary breast cancerhttps://orcid.org/0000-0002-6963-5472МихайловИ. В.MikhailovI. V.

Михайлов Илья Владимирович - кандидат медицинских наук, заведующий отделением противоопухолевой лекарственной терапии.

129110, Москва, ул. Щепкина, 61/2

Ilya V. Mikhailov - MD, PhD, Head of the Department of Antitumor Drug Therapy.

61/2, Shchepkina St., Moscow, 129110

ГребенникИ. В.GrebennikI. V.

Гребенник Иван Валерьевич - стажер-исследователь лаборатории биофизики.

117198, Москва, ул. Саморы Машела, 1

Ivan V. Grebennik - Intern-Researcher, Laboratory of Biophysics.

1, Samory Mashela St., Moscow, 117198

https://orcid.org/0000-0001-6122-0638ГлазковА. А.GlazkovA. A.

Глазков Алексей Андреевич - кандидат медицинских наук, старший научный сотрудник лаборатории медико-физических исследований

SPIN-код: 3250-1882

Author ID (Scopus): 57199329515

ResearcherID (WOS): R-7373-2016

129110, Москва, ул. Щепкина, 61/2

Alexey A. Glazkov - MD, PhD, Senior Researcher, Laboratory of Medical and Physical Research

Author ID (Scopus): 57199329515

ResearcherID (WOS): R-7373-2016

61/2, Shchepkina St., Moscow, 129110

https://orcid.org/0000-0001-7955-349XКругловаИ. А.KruglovaI. A.

Круглова Ирина Александровна - врач клинико-диагностической лаборатории.

603089, Нижний Новгород, ул. Республиканская, 47

Irina A. Kruglova – MD.

47, Respublikanskaya St., Nizhny Novgorod, 603089

https://orcid.org/0000-0001-5946-0026КузнецоваС. А.KuznetsovaS. A.

Кузнецова Софья Алексеевна - кандидат физико-математических наук, ведущий научный сотрудник лаборатории биофизики, ФГБУ «НМИЦ детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; старший научный сотрудник, ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН.

ResearcherID (WOS): N-1383-2014

117198, Москва, ул. Саморы Машела, 1; 109029, Москва, ул. Средняя Калитниковская, 30

Sofya A. Kuznetsova - PhD, Leading Researcher, Laboratory of Biophysics, D. Rogachev NRCPH, OI, Ministry of Health of Russia; Senior Researcher, Centre for Theoretical Problems of Physicochemical Pharmacology of the RAS

ResearcherID (WOS): N-1383-2014

1, Samory Mashela St., Moscow, 117198; 30, Srednyaya Kalitnikovskaya St., Moscow, 109029

https://orcid.org/0000-0002-1601-9780БалкановА. С.BalkanovA. S.

Балканов Андрей Сергеевич - доктор медицинских наук, руководитель отделения радиотерапии

SPIN-код: 5757-4455

Author ID (Scopus): 6508333085

129110, Москва, ул. Щепкина, 61/2

Andrey S. Balkanov - MD, DSc, Head of Radiotherapy Department

Author ID (Scopus): 6508333085

61/2, Shchepkina St., Moscow, 129110

andreybalkanov@yandex.ruГБУЗ МО Московский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияM.F. Vladimirsky Moscow Regional Research and Clinical instituteRussian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииРоссияD. Rogachev National Research Centre for Pediatric Hematology, Oncology and immunology, Ministry of Health of RussiaRussian FederationГБУЗ НО «Городская больница 35 г. Нижнего Новгорода»РоссияCity Hospital No. 35Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России; ФГБУН «Центр теоретических проблем физико-химической фармакологии» Российской академии наукРоссияD. Rogachev National Research Centre for Pediatric Hematology, Oncology and immunology, Ministry of Health of Russia; Centre for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of SciencesRussian Federation2026170520262526779Copyright © Михайлов И.В., Гребенник И.В., Глазков А.А., Круглова И.А., Кузнецова С.А., Балканов А.С., 20262026Михайлов И.В., Гребенник И.В., Глазков А.А., Круглова И.А., Кузнецова С.А., Балканов А.С.Mikhailov I.V., Grebennik I.V., Glazkov A.A., Kruglova I.A., Kuznetsova S.A., Balkanov A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/4201

Циркулирующие в крови опухолевые клетки (ЦОК) часто исследуют с точки зрения их прогностической значимости при системной терапии в периоперационном периоде (СТпери) первичного рака молочной железы (пРМЖ). Пока не ясно, существуют ли уникальные особенности изменения параметров ЦОК, которые можно использовать в качестве предиктора эффективности неоадъювантной (неоСТ) или адъювантной (аСТ) системной терапии.

Цель исследования – сравнительный анализ параметров однократно выделенных ЦОК у пациенток с пРМЖ с высоким риском прогрессирования, получающих неоСТ или аСТ.

Материал и методы

Материал и методы. В исследование включено 39 пациенток с пРМЖ, получивших неоСТ (1-я группа, n=16) или аСТ (2-я группа, n=23). Забор крови для выделения ЦОК методом микрофильтрации осуществлялся однократно, после 2–5 циклов СТпери.

Результаты

Результаты. Количество ЦОК позитивных пациенток (1-я группа – 87,5 %, 2-я группа – 82,6 % пациенток), частота выделения 5 и более ЦОК (37,5 и 52,2 % пациенток в 1-й и 2-й группах соответственно, р=0,563), а также кластеров ЦОК (у 56,2 и у 43,5 % пациенток в 1-й и 2-й группах соответственно, р=0,646) в группах неоСТ или аСТ оказались сравнимыми. Не установлено существенных различий количественных параметров (Ме) ЦОК (1-я группа – 3 [1,8; 7,8] ЦОК, 2-я группа – 5 [2; 6,5] ЦОК, р=0,785). Вне зависимости от группы у большинства пациенток кластеры ЦОК состояли из 2–3 клеток (в 1-й группе у 88,9 %, во 2-й – у 100 % пациенток). При СТпери выделение большого числа ЦОК ассоциировалось с обнаружением кластеров ЦОК и наличием лимфогенных метастазов.

Заключение

Заключение. При неоСТ и аСТ количество и характеристики ЦОК существенно не отличались, что может указывать на незначительное влияние резекции молочной железы на вышеперечисленные параметры. Полученные данные также могут свидетельствовать о сравнимой прогностической значимости параметров выделенных ЦОК у пациенток с пРМЖ при прогнозе эффективности СТпери безотносительно последовательности, в которой осуществлялись системная терапия и хирургическое вмешательство.

Circulating tumor cells (CTCs) are frequently studied in terms of their prognostic significance during perioperative systemic therapy (periST) for breast cancer (BC). it is not yet clear whether there are unique changes in the CTC parameters that could be used as a predictor of the effectiveness of neoadjuvant (neoST) or adjuvant (aST) systemic therapy.

The aim of the study was a comparative analysis of parameters of once-isolated CTCs in BC patients with high risk of progression, who received neoST or aST.

Material and Methods

Material and Methods. The study included BC 39 patients who received neo-ST (group 1: 16 patients) or aST (group 2: 23 patients). Blood sampling for CTC isolation using microfiltration was performed after 2–5 cycles of periST.

Results

Results. No significant differences in the number of CTC-positive patients (87.5 % in group1 and 82.6 % in group 2) and the frequency of isolation of 5 or more CTCs (37.5 % in group 1 and 52.2 % in group 2, p=0.563), as well as CTC clusters (56.2 % and 43.5 % of patients in groups 1 and 2 groups, respectively, p=0.646) between the neoST and aST groups were found. There were no significant differences in the quantitative parameters (Me) of CTCs between the groups (1 group – 3 [1.8; 7.8] CTCs, 2 group – 5 [2; 6.5] CTCs, p=0.785). Regardless of the group, most patients had CTC clusters consisting of 2 to 3 cells (88.9 % and 100 % of patients in groups 1 and 2, respectively). During peri ST, a high count of CTCs was associated with the detection of CTC clusters and the presence of lymphatic metastases.

Conclusion

Conclusion. No significant differences in CTC count and characteristics between the neoST and aST groups were found. it indicates that breast tumor resection has a minor effect on CTC parameters. . The findings highlight that CTCs hold similar prognostic value regardless of whether they are measured before or after surgery, aiding in the prediction of periST.

рак молочной железыциркулирующие опухолевые клеткикластерысистемная терапияпериоперационный периодмикрофильтрацияцитологический анализbreast cancercirculating tumor cellsclusterssystemic therapyperioperative periodmicrofiltrationcytological analysisВыделение и анализ ЦОК выполнялись за счет гранта Российского Научного Фонда (проект № 2345-10039)The isolation and analysis of CTCs were carried out with the support of a grant from the Russian Science Foundation (project No. 23-45-10039)ReferencesSiegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1): 7–33. doi: 10.3322/caac.21708.Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1): 7–33. doi: 10.3322/caac.21708.Гуров А.Н., Балканов А.С., Катунцева Н.А., Огнева Е.Ю. Анализ онкозаболеваемости и смертности населения Московской области за 2014 год. Альманах клинической медицины. 2015; (41): 6–11. doi: 10.18786/2072-0505-2015-41-6-11. EDN: UMQBEB.Gurov A.N., Balkanov A.S., Katuntseva N.A., Ogneva E.Y. The analysis of cancer incidence and mortality among the population of the Moscow region in 2014. Almanac of Clinical Medicine. 2015; (41): 6–11. (in Russian). doi: 10.18786/2072-0505-2015-41-6-11. EDN: UMQBEB.Dillekås H., Rogers M.S., Straume O. Are 90 % of deaths from cancer caused by metastases? Cancer Med. 2019; 8(12): 5574–76. doi: 10.1002/cam4.2474.Dillekås H., Rogers M.S., Straume O. Are 90 % of deaths from cancer caused by metastases? Cancer Med. 2019; 8(12): 5574–76. doi: 10.1002/cam4.2474.Mariotto A.B., Zou Z., Zhang F., Howlader N., Kurian A.W., Etzioni R. Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2018; 27(11):1332–41. doi: 10.1158/1055-9965.EPI-17-1129.Mariotto A.B., Zou Z., Zhang F., Howlader N., Kurian A.W., Etzioni R. Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2018; 27(11):1332–41. doi: 10.1158/1055-9965.EPI-17-1129.Ibragimova M.K., Tsyganov M.M., Kravtsova E.A., Tsydenova I.A., Litviakov N.V. Organ-specificity of breast cancer metastasis. Int J Mol Sci. 2023; 24(21): 15625. doi: 10.3390/ijms242115625.Ibragimova M.K., Tsyganov M.M., Kravtsova E.A., Tsydenova I.A., Litviakov N.V. Organ-specificity of breast cancer metastasis. Int J Mol Sci. 2023; 24(21): 15625. doi: 10.3390/ijms242115625.Mohamed R.F., Abdelhameed D.H., Mohamed M.A. Combination of anatomical and biological factors to predict disease-free survival in breast cancer. JCO Glob Oncol. 2023; 9: e2200269. doi: 10.1200/GO.22.00269.Mohamed R.F., Abdelhameed D.H., Mohamed M.A. Combination of anatomical and biological factors to predict disease-free survival in breast cancer. JCO Glob Oncol. 2023; 9: e2200269. doi: 10.1200/GO.22.00269.Liu D., Chang L., Hao Q., Ren X., Liu P., Liu X., Wei Y., Wang M., Wu H., Kang H., Lin S. Is neoadjuvant chemotherapy necessary for T2N01M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery? J Cancer Res Clin Oncol. 2024; 150(5): 285. doi: 10.1007/s00432-024-05810-6.Liu D., Chang L., Hao Q., Ren X., Liu P., Liu X., Wei Y., Wang M., Wu H., Kang H., Lin S. Is neoadjuvant chemotherapy necessary for T2N01M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery? J Cancer Res Clin Oncol. 2024; 150(5): 285. doi: 10.1007/s00432-024-05810-6.Mason S.R., Willson M.L., Egger S.J., Beith J., Dear R.F., Goodwin A. Platinum chemotherapy for early triple-negative breast cancer. Breast. 2024; 75: 103712. doi: 10.1016/j.breast.2024.103712.Mason S.R., Willson M.L., Egger S.J., Beith J., Dear R.F., Goodwin A. Platinum chemotherapy for early triple-negative breast cancer. Breast. 2024; 75: 103712. doi: 10.1016/j.breast.2024.103712.Ghasemi F., Brackstone M. The impact of neoadjuvant versus adjuvant chemotherapy on survival outcomes in locally advanced breast cancer. Curr Oncol. 2024; 31(10): 6007–16. doi: 10.3390/curroncol31100448.Ghasemi F., Brackstone M. The impact of neoadjuvant versus adjuvant chemotherapy on survival outcomes in locally advanced breast cancer. Curr Oncol. 2024; 31(10): 6007–16. doi: 10.3390/curroncol31100448.Akbari M.E., Ghelichi-Ghojogh M., Nikeghbalian Z., Karami M., Akbari A., Hashemi M., Nooraei S., Ghiasi M., Fararouei M., Moradian F. Neoadjuvant vs adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study. Ann Med Surg (Lond). 2022; 84: 104921. doi: 10.1016/j.amsu.2022.104921.Akbari M.E., Ghelichi-Ghojogh M., Nikeghbalian Z., Karami M., Akbari A., Hashemi M., Nooraei S., Ghiasi M., Fararouei M., Moradian F. Neoadjuvant vs adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study. Ann Med Surg (Lond). 2022; 84: 104921. doi: 10.1016/j.amsu.2022.104921.Pierga J.Y., Bidard F.C., Autret A., Petit T., Andre F., Dalenc F., Levy C., Ferrero J.M., Romieu G., Bonneterre J., Lerebours F., Bachelot T., Kerbrat P., Campone M., Eymard J.C., Mouret-Reynier M.A., Gligorov J., Hardy-Bessard A.C., Lortholary A., Soulie P., Boher J.M., Proudhon C., Charafe-Jaufret E., Lemonnier J., Bertucci F., Viens P. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 2017; 28(1): 103–109. doi: 10.1093/annonc/mdw535.Pierga J.Y., Bidard F.C., Autret A., Petit T., Andre F., Dalenc F., Levy C., Ferrero J.M., Romieu G., Bonneterre J., Lerebours F., Bachelot T., Kerbrat P., Campone M., Eymard J.C., Mouret-Reynier M.A., Gligorov J., Hardy-Bessard A.C., Lortholary A., Soulie P., Boher J.M., Proudhon C., Charafe-Jaufret E., Lemonnier J., Bertucci F., Viens P. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 2017; 28(1): 103–109. doi: 10.1093/annonc/mdw535.Bidard F.C., Michiels S., Riethdorf S., Mueller V., Esserman L.J., Lucci A., Naume B., Horiguchi J., Gisbert-Criado R., Sleijfer S., Toi M., Garcia-Saenz J.A., Hartkopf A., Generali D., Rothé F., Smerage J., Muinelo-Romay L., Stebbing J., Viens P., Magbanua M.J.M., Hall C.S., Engebraaten O., Takata D., Vidal-Martínez J., Onstenk W., Fujisawa N., Diaz-Rubio E., Taran F.A., Cappelletti M.R., Ignatiadis M., Proudhon C., Wolf D.M., Bauldry J.B., Borgen E., Nagaoka R., Carañana V., Kraan J., Maestro M., Brucker S.Y., Weber K., Reyal F., Amara D., Karhade M.G., Mathiesen R.R., Tokiniwa H., Llombart-Cussac A., Meddis A., Blanche P., d’Hollander K., Cottu P., Park J.W., Loibl S., Latouche A., Pierga J.Y., Pantel K. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018; 110(6): 560–67. doi: 10.1093/jnci/djy018.Bidard F.C., Michiels S., Riethdorf S., Mueller V., Esserman L.J., Lucci A., Naume B., Horiguchi J., Gisbert-Criado R., Sleijfer S., Toi M., Garcia-Saenz J.A., Hartkopf A., Generali D., Rothé F., Smerage J., Muinelo-Romay L., Stebbing J., Viens P., Magbanua M.J.M., Hall C.S., Engebraaten O., Takata D., Vidal-Martínez J., Onstenk W., Fujisawa N., Diaz-Rubio E., Taran F.A., Cappelletti M.R., Ignatiadis M., Proudhon C., Wolf D.M., Bauldry J.B., Borgen E., Nagaoka R., Carañana V., Kraan J., Maestro M., Brucker S.Y., Weber K., Reyal F., Amara D., Karhade M.G., Mathiesen R.R., Tokiniwa H., Llombart-Cussac A., Meddis A., Blanche P., d’Hollander K., Cottu P., Park J.W., Loibl S., Latouche A., Pierga J.Y., Pantel K. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018; 110(6): 560–67. doi: 10.1093/jnci/djy018.Zhou J., Wu J., Hao X., Li P., Zhang H., Wu X., Chen J., Liu J., Xiao J., Zhang S., Jiang Z., Yang Y., Hu Z., Wang T. An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2positive early breast cancer. Front Oncol. 2022; 12:966624. doi: 10.3389/fonc.2022.966624.Zhou J., Wu J., Hao X., Li P., Zhang H., Wu X., Chen J., Liu J., Xiao J., Zhang S., Jiang Z., Yang Y., Hu Z., Wang T. An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2positive early breast cancer. Front Oncol. 2022; 12:966624. doi: 10.3389/fonc.2022.966624.Shliakhtunou Y.A. CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study. Breast Cancer Res Treat. 2021; 186(2): 439–51. doi: 10.1007/s10549-02006036-z.Shliakhtunou Y.A. CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study. Breast Cancer Res Treat. 2021; 186(2): 439–51. doi: 10.1007/s10549-02006036-z.Zhao H., Wang L., Fang C., Li C., Zhang L. Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients. Front Oncol. 2023; 13: 1272788. doi: 10.3389/fonc.2023.1272788.Zhao H., Wang L., Fang C., Li C., Zhang L. Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients. Front Oncol. 2023; 13: 1272788. doi: 10.3389/fonc.2023.1272788.Pang S., Li H., Xu S., Feng L., Ma X., Chu Y., Zou B., Wang S., Zhou G. Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer. Sci Rep. 2021; 11(1): 13441. doi: 10.1038/s41598-021-92876-8.Pang S., Li H., Xu S., Feng L., Ma X., Chu Y., Zou B., Wang S., Zhou G. Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer. Sci Rep. 2021; 11(1): 13441. doi: 10.1038/s41598-021-92876-8.Jakabova A., Bielcikova Z., Pospisilova E., Petruzelka L., Blasiak P., Bobek V., Kolostova K. Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. Ther Adv Med Oncol. 2021; 13: 17588359211028492. doi: 10.1177/17588359211028492.Jakabova A., Bielcikova Z., Pospisilova E., Petruzelka L., Blasiak P., Bobek V., Kolostova K. Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. Ther Adv Med Oncol. 2021; 13: 17588359211028492. doi: 10.1177/17588359211028492.Ma G., Wang J., Fu J., Chen .R, Liang M., Li M., Xia T., Liu X., Wang S. Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer. Breast Cancer Res Treat. 2023; 201(1): 27–41. doi: 10.1007/s10549-023-06942-y.Ma G., Wang J., Fu J., Chen .R, Liang M., Li M., Xia T., Liu X., Wang S. Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer. Breast Cancer Res Treat. 2023; 201(1): 27–41. doi: 10.1007/s10549-023-06942-y.Galardi F., De Luca F., Biagioni C., Migliaccio I., Curigliano G., Minisini A.M., Bonechi M., Moretti E., Risi E., McCartney A., Benelli M., Romagnoli D., Cappadona S., Gabellini S., Guarducci C., Conti V., Biganzoli L., Di Leo A., Malorni L. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021; 23(1): 38. doi: 10.1186/s13058-021-01415-w.Galardi F., De Luca F., Biagioni C., Migliaccio I., Curigliano G., Minisini A.M., Bonechi M., Moretti E., Risi E., McCartney A., Benelli M., Romagnoli D., Cappadona S., Gabellini S., Guarducci C., Conti V., Biganzoli L., Di Leo A., Malorni L. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021; 23(1): 38. doi: 10.1186/s13058-021-01415-w.Rack B., Schindlbeck C., Jückstock J., Andergassen U., Hepp P., Zwingers T., Friedl T.W., Lorenz R., Tesch H., Fasching P.A., Fehm T., Schneeweiss A., Lichtenegger W., Beckmann M.W., Friese K., Pantel K., Janni W.; SUCCESS Study Group. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5): dju066. doi: 10.1093/jnci/dju066.Rack B., Schindlbeck C., Jückstock J., Andergassen U., Hepp P., Zwingers T., Friedl T.W., Lorenz R., Tesch H., Fasching P.A., Fehm T., Schneeweiss A., Lichtenegger W., Beckmann M.W., Friese K., Pantel K., Janni W.; SUCCESS Study Group. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5): dju066. doi: 10.1093/jnci/dju066.Brady L., Hayes B., Sheill G., Baird A.M., Guinan E., Stanfill B., Vlajnic T., Casey O., Murphy V., Greene J., Allott E.H., Hussey J., Cahill F., van Hemelrijck M., Peat N., Mucci L., Cunningham M., Grogan L., Lynch T., Manecksha R.P., McCaffrey J., O’Donnell D., Sheils O., O’Leary J., Rudman S., McDermott R., Finn S. Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS One. 2020; 15(12): e0243928. doi: 10.1371/journal.pone.0243928.Brady L., Hayes B., Sheill G., Baird A.M., Guinan E., Stanfill B., Vlajnic T., Casey O., Murphy V., Greene J., Allott E.H., Hussey J., Cahill F., van Hemelrijck M., Peat N., Mucci L., Cunningham M., Grogan L., Lynch T., Manecksha R.P., McCaffrey J., O’Donnell D., Sheils O., O’Leary J., Rudman S., McDermott R., Finn S. Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS One. 2020; 15(12): e0243928. doi: 10.1371/journal.pone.0243928.Kuvendjiska J., Pitman M.B., Martini V., Braun C., Grebe K., Timme S., Fichtner-Feigl S., Glatz T., Schmoor C., Guenzle J., Hoeppner J., Kulemann B. Cytopathological heterogeneity of circulating tumor cells in non-metastatic esophageal adenocarcinoma. Anticancer Res. 2020; 40(10): 5679–85. doi: 10.21873/anticanres.14582.Kuvendjiska J., Pitman M.B., Martini V., Braun C., Grebe K., Timme S., Fichtner-Feigl S., Glatz T., Schmoor C., Guenzle J., Hoeppner J., Kulemann B. Cytopathological heterogeneity of circulating tumor cells in non-metastatic esophageal adenocarcinoma. Anticancer Res. 2020; 40(10): 5679–85. doi: 10.21873/anticanres.14582.Волченко Н.Н., Славнова Е.Н., Гладунова З.Д., Тугулукова А.А., Митина Л.А., Сухарев С.С., Спиридонов И.Н., Самородов А.В., Медовый В.С., Тычинский В.П., Решетов И.В., Кретушев А.В., Вышенская Т.В., Клемешов И.В. Современная цитологическая диагностика заболеваний молочной железы. Под ред. Н.Н. Волченко, Е.Н. Славновой. М., 2014. 198 с. ISBN: 978-5-7038-3993-5. EDN: VYBANF.Volchenko N.N., Slavnova E.N., Gladunova Z.D., Tugulukova A.A., Mitina L.A., Sukharev S.S., Spiridonov I.N., Samorodov A.V., Medovyi V.S., Tychinskii V.P., Reshetov I.V., Kretushev A.V., Vyshenskaya T.V., Klemeshov I.V. Modern cytological diagnostics of breast diseases; eds. N.N. Volchenko, E.N. Slavnova. Moscow, 2014; 198 p. (in Russian). ISBN: 978-5-7038-3993-5. EDN: VYBANF.Adams D.L., Stefansson S., Haudenschild C., Martin S.S., Charpentier M., Chumsri S., Cristofanilli M., Tang C.M., Alpaugh R.K.. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Cytometry A. 2015; 87(2): 137–44. doi: 10.1002/cyto.a.22613.Adams D.L., Stefansson S., Haudenschild C., Martin S.S., Charpentier M., Chumsri S., Cristofanilli M., Tang C.M., Alpaugh R.K.. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Cytometry A. 2015; 87(2): 137–44. doi: 10.1002/cyto.a.22613.Du K.Y., Wu S., Ma X., Liu Y. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study. Breast Cancer Res Treat. 2024; 207(3): 517–27. doi: 10.1007/s10549-024-07430-7.Du K.Y., Wu S., Ma X., Liu Y. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study. Breast Cancer Res Treat. 2024; 207(3): 517–27. doi: 10.1007/s10549-024-07430-7.Tseng J., Yang C., Liang S., Liu R., Jiang J., Lin C. Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers (Basel). 2014; 6(4): 2369–86. doi: 10.3390/ cancers6042369.Tseng J., Yang C., Liang S., Liu R., Jiang J., Lin C. Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers (Basel). 2014; 6(4): 2369–86. doi: 10.3390/ cancers6042369.Lopresti A., Acquaviva C., Boudin L., Finetti P., Garnier S., Aulas A., Liberatoscioli M.L., Cabaud O., Guille A., de Nonneville A., Da Costa Q., Denicolai E., Pakradouni J., Goncalves A., Birnbaum D., Bertucci F., Mamessier E. Identification of atypical circulating tumor cells with prognostic value in metastatic breast cancer patients. Cancers (Basel). 2022; 14(4): 932. doi: 10.3390/cancers14040932.Lopresti A., Acquaviva C., Boudin L., Finetti P., Garnier S., Aulas A., Liberatoscioli M.L., Cabaud O., Guille A., de Nonneville A., Da Costa Q., Denicolai E., Pakradouni J., Goncalves A., Birnbaum D., Bertucci F., Mamessier E. Identification of atypical circulating tumor cells with prognostic value in metastatic breast cancer patients. Cancers (Basel). 2022; 14(4): 932. doi: 10.3390/cancers14040932.Воловецкий А.Б., Малинина П.А., Капитанникова А.Ю., Сметанина С.В., Круглова И.А., Масленникова А.В. Выделение циркулирующих опухолевых клеток из образцов периферической крови онкологических больных с помощью микрофлюидной технологии. Современные технологии в медицине. 2020; 12(6): 62–69. doi: 10.17691/stm2020.12.6.08. EDN: EYKDDH.Volovetskiy A.B., Malinina P.A., Kapitannikova A.Y., Smetanina S.V., Kruglova I.A., Maslennikova A.V. Isolation of circulating tumor cells from peripheral blood samples of cancer patients using microfluidic technology. Modern Technology in Medicine. 2020; 12(6): 62–69. (in Russian). doi: 10.17691/stm2020.12.6.08. EDN: EYKDDH.Kulemann B., Pitman M.B., Liss A.S., Valsangkar N., FernándezDel Castillo C., Lillemoe K.D., Hoeppner J., Mino-Kenudson M., Warshaw A.L., Thayer S.P. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas. 2015; 44(4): 547–50. doi: 10.1097/MPA.0000000000000324.Kulemann B., Pitman M.B., Liss A.S., Valsangkar N., FernándezDel Castillo C., Lillemoe K.D., Hoeppner J., Mino-Kenudson M., Warshaw A.L., Thayer S.P. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas. 2015; 44(4): 547–50. doi: 10.1097/MPA.0000000000000324.Zheng X., Fan L., Zhou P., Ma H., Huang S., Yu D., Zhao L., Yang S., Liu J., Huang A., Cai C., Dai X., Zhang T. Detection of circulating tumor cells and circulating tumor microemboli in gastric cancer. Transl Oncol. 2017; 10(3): 431–41. doi: 10.1016/j.tranon.2017.02.007.Zheng X., Fan L., Zhou P., Ma H., Huang S., Yu D., Zhao L., Yang S., Liu J., Huang A., Cai C., Dai X., Zhang T. Detection of circulating tumor cells and circulating tumor microemboli in gastric cancer. Transl Oncol. 2017; 10(3): 431–41. doi: 10.1016/j.tranon.2017.02.007.Huebner H., Fasching P.A., Gumbrecht W., Jud S., Rauh C., Matzas M., Paulicka P., Friedrich K., Lux M.P., Volz B., Gass P., Häberle L., Meier-Stiegen F., Hartkopf A., Neubauer H., Almstedt K., Beckmann M.W., Fehm T.N., Ruebner M. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer. 2018; 18(1): 204. doi: 10.1186/s12885-018-4115-1.Huebner H., Fasching P.A., Gumbrecht W., Jud S., Rauh C., Matzas M., Paulicka P., Friedrich K., Lux M.P., Volz B., Gass P., Häberle L., Meier-Stiegen F., Hartkopf A., Neubauer H., Almstedt K., Beckmann M.W., Fehm T.N., Ruebner M. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer. 2018; 18(1): 204. doi: 10.1186/s12885-018-4115-1.Peruzzi C., Di Cosimo S., Gerratana L., Motta R., Martinetti A., Vingiani A., D’Amico P., Zhang Y., Vismara M., Depretto C., Scaperrotta G., Folli S., Pruneri G., Cristofanilli M., Daidone M.G., Cappelletti V. Сirculating tumor cell clusters are frequently detected in women with early-stage breast cancer. Cancers (Basel). 2021; 13(10): 2356. doi: 10.3390/cancers13102356.Peruzzi C., Di Cosimo S., Gerratana L., Motta R., Martinetti A., Vingiani A., D’Amico P., Zhang Y., Vismara M., Depretto C., Scaperrotta G., Folli S., Pruneri G., Cristofanilli M., Daidone M.G., Cappelletti V. Сirculating tumor cell clusters are frequently detected in women with early-stage breast cancer. Cancers (Basel). 2021; 13(10): 2356. doi: 10.3390/cancers13102356.Hall C., Karhade M., Laubacher B., Anderson A., Kuerer H., DeSynder S., Lucci A. Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann Surg Oncol. 2015; 22 (s3): 552–58. doi: 10.1245/s10434-015-4600-6.Hall C., Karhade M., Laubacher B., Anderson A., Kuerer H., DeSynder S., Lucci A. Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann Surg Oncol. 2015; 22 (s3): 552–58. doi: 10.1245/s10434-015-4600-6.Hall C.S., Karhade M.G., Bowman Bauldry J.B., Valad L.M., Kuerer H.M., DeSnyder S.M., Lucci A. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg. 2016; 223(1): 20–29. doi: 10.1016/j.jamcollsurg.2016.02.021.Hall C.S., Karhade M.G., Bowman Bauldry J.B., Valad L.M., Kuerer H.M., DeSnyder S.M., Lucci A. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg. 2016; 223(1): 20–29. doi: 10.1016/j.jamcollsurg.2016.02.021.Gwark S., Kim J., Kwon N.J., Kim K.Y., Kim Y., Lee C.H., Kim Y.H., Kim M.S., Hong S.W., Choi M.Y., Jeon B.H., Chang S., Yu J., Park J.Y., Lee H.J., Lee S.B., Chung I.Y., Ko B.S., Kim H.J., Lee J.W., Son B.H., Ahn J.H., Jung K.H., Kim S.B., Gong G.Y., Ahn S.H.. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. Sci Rep. 2020; 10(1): 17466. doi: 10.1038/s41598-02074577-w.Gwark S., Kim J., Kwon N.J., Kim K.Y., Kim Y., Lee C.H., Kim Y.H., Kim M.S., Hong S.W., Choi M.Y., Jeon B.H., Chang S., Yu J., Park J.Y., Lee H.J., Lee S.B., Chung I.Y., Ko B.S., Kim H.J., Lee J.W., Son B.H., Ahn J.H., Jung K.H., Kim S.B., Gong G.Y., Ahn S.H.. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. Sci Rep. 2020; 10(1): 17466. doi: 10.1038/s41598-02074577-w.Li M., Liu Y., Han X., Li T., Zhang Z., Xue N., Liang M., Ma G., Xia T. Aneuploid circulating endothelial cells with prognostic value in locally advanced breast cancer patients after neoadjuvant chemotherapy. Breast Cancer (Dove Med Press). 2024; 16: 761–68. doi: 10.2147/BCTT.S487336.Li M., Liu Y., Han X., Li T., Zhang Z., Xue N., Liang M., Ma G., Xia T. Aneuploid circulating endothelial cells with prognostic value in locally advanced breast cancer patients after neoadjuvant chemotherapy. Breast Cancer (Dove Med Press). 2024; 16: 761–68. doi: 10.2147/BCTT.S487336.Mäurer M., Schott D., Pizon M., Drozdz S., Wendt T., Wittig A., Pachmann K. Increased circulating epithelial tumor cells (CETC/CTC) over the course of adjuvant radiotherapy is a predictor of less favorable outcome in patients with early-stage breast cancer. Curr Oncol. 2022; 30(1): 261–73. doi: 10.3390/curroncol30010021.Mäurer M., Schott D., Pizon M., Drozdz S., Wendt T., Wittig A., Pachmann K. Increased circulating epithelial tumor cells (CETC/CTC) over the course of adjuvant radiotherapy is a predictor of less favorable outcome in patients with early-stage breast cancer. Curr Oncol. 2022; 30(1): 261–73. doi: 10.3390/curroncol30010021.Wang G., Zhang S., Wang M., Liu L., Liu Y., Tang L., Bai H., Zhao H. Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis. BMC Cancer. 2021; 21(1): 875. doi: 10.1186/s12885-021-08582-1.Wang G., Zhang S., Wang M., Liu L., Liu Y., Tang L., Bai H., Zhao H. Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis. BMC Cancer. 2021; 21(1): 875. doi: 10.1186/s12885-021-08582-1.Lai H.C., Huang H.H., Hao Y.J., Lee H.L., Wang C.C., Ling T.Y., Wu J.K., Tseng F.G. A preliminary analysis of circulating tumor microemboli from breast cancer patients during follow-up visits. Curr Oncol. 2024; 31(9): 5677–93. doi: 10.3390/curroncol31090421.Lai H.C., Huang H.H., Hao Y.J., Lee H.L., Wang C.C., Ling T.Y., Wu J.K., Tseng F.G. A preliminary analysis of circulating tumor microemboli from breast cancer patients during follow-up visits. Curr Oncol. 2024; 31(9): 5677–93. doi: 10.3390/curroncol31090421.Mendelaar P.A.J., Kraan J., Van M., Zeune L.L., Terstappen L.W.M.M., Oomen-de Hoop E., Martens J.W.M., Sleijfer S. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients. Mol Oncol. 2021; 15(1): 116–25. doi: 10.1002/1878-0261.12802.Mendelaar P.A.J., Kraan J., Van M., Zeune L.L., Terstappen L.W.M.M., Oomen-de Hoop E., Martens J.W.M., Sleijfer S. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients. Mol Oncol. 2021; 15(1): 116–25. doi: 10.1002/1878-0261.12802.

The authors declare that there are no conflicts of interest present.